JiangXi Tianxin Pharmaceutical Co., Ltd. (SHA:603235)

SHA:603235 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	1,755	1,570	1,078	2,308	2,070	717.08
Trading Asset Securities	-	-	481.69	-	230	-
Cash & Short-Term Investments	1,755	1,570	1,560	2,308	2,300	717.08
Cash Growth	15.08%	0.62%	-32.40%	0.35%	220.73%	-29.65%
Accounts Receivable	430.82	460.26	414.28	284.34	357.31	418.96
Other Receivables	5.68	3.03	1.4	1.7	2.03	2.23
Receivables	436.49	463.29	415.68	286.05	359.35	421.19
Inventory	732.19	569.89	589.23	478.97	470.63	405.54
Other Current Assets	73.18	179.98	130.46	48.47	36.4	35.58
Total Current Assets	2,997	2,783	2,695	3,121	3,166	1,579
Property, Plant & Equipment	3,137	3,104	2,585	1,618	1,311	1,183
Long-Term Investments	-	-	-	0.03	0.4	-
Other Intangible Assets	185.51	188.48	188.16	192.31	109.81	111.8
Long-Term Deferred Tax Assets	85.82	90.9	83.18	81.13	58.6	61.46
Long-Term Deferred Charges	15.91	14.73	9.61	10.99	12.38	4.04
Other Long-Term Assets	34.43	8.34	42.11	66.05	21.95	12.45
Total Assets	6,456	6,190	5,603	5,090	4,680	2,952

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	287.61	312.22	250.13	138.07	108.55	121.11
Accrued Expenses	92.82	143.55	125.76	115.86	112.97	100.66
Short-Term Debt	201	7.33	16.06	100.07	-	300.3
Current Portion of Long-Term Debt	243.32	83.67	10.1	-	-	14.02
Current Portion of Leases	-	0.91	3.28	3.12	3.42	3.33
Current Income Taxes Payable	19.56	24.54	23.45	30.68	0.5	49.01
Current Unearned Revenue	22.65	18.29	24.02	21.1	23.34	19.71
Other Current Liabilities	86.01	45.08	56.98	52.42	62.4	68.92
Total Current Liabilities	952.97	635.59	509.78	461.33	311.18	677.06
Long-Term Debt	92.89	299.84	117.43	-	-	26.04
Long-Term Leases	12.25	13.18	1.82	5.1	4.65	7.98
Long-Term Unearned Revenue	300	324.6	358.37	390.79	306.16	332.49
Total Liabilities	1,358	1,273	987.41	857.21	621.98	1,044

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	437.78	437.78	437.78	437.78	437.78	394
Additional Paid-In Capital	2,002	2,002	1,997	1,987	1,977	493.58
Retained Earnings	2,718	2,537	2,241	1,808	1,643	1,021
Treasury Stock	-60.01	-60.01	-60.01	-	-	-
Shareholders' Equity	5,097	4,917	4,616	4,233	4,058	1,909
Total Liabilities & Equity	6,456	6,190	5,603	5,090	4,680	2,952

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	549.46	404.92	148.69	108.29	8.07	351.68
Net Cash (Debt)	1,206	1,165	1,411	2,200	2,292	365.41
Net Cash Growth	4.55%	-17.47%	-35.84%	-4.03%	527.19%	-45.78%
Net Cash Per Share	2.76	2.66	3.23	5.04	5.56	0.93
Filing Date Shares Outstanding	424.94	435.17	435.17	436.41	437.78	394
Total Common Shares Outstanding	424.94	435.17	435.17	437.78	437.78	394
Working Capital	2,044	2,147	2,186	2,660	2,855	902.34
Book Value Per Share	12.00	11.30	10.61	9.67	9.27	4.84
Tangible Book Value	4,912	4,728	4,428	4,041	3,948	1,797
Tangible Book Value Per Share	11.56	10.86	10.17	9.23	9.02	4.56
Buildings	-	1,287	847.28	655.11	596.5	552.3
Machinery	-	1,860	1,499	1,257	1,189	1,056
Construction In Progress	-	1,007	1,117	435.37	122.64	51.69

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error